PL2611445T3 - Kompozycje buprenorfiny w dużej dawce i ich zastosowanie jako środka przeciwbólowego - Google Patents

Kompozycje buprenorfiny w dużej dawce i ich zastosowanie jako środka przeciwbólowego

Info

Publication number
PL2611445T3
PL2611445T3 PL11758027T PL11758027T PL2611445T3 PL 2611445 T3 PL2611445 T3 PL 2611445T3 PL 11758027 T PL11758027 T PL 11758027T PL 11758027 T PL11758027 T PL 11758027T PL 2611445 T3 PL2611445 T3 PL 2611445T3
Authority
PL
Poland
Prior art keywords
analgesic
high dose
dose buprenorphine
buprenorphine compositions
compositions
Prior art date
Application number
PL11758027T
Other languages
English (en)
Inventor
Rachel A. Richardson
Carmela H. Luangdilok
Original Assignee
Zoetis Belgium S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Belgium S.A. filed Critical Zoetis Belgium S.A.
Publication of PL2611445T3 publication Critical patent/PL2611445T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11758027T 2010-09-03 2011-09-02 Kompozycje buprenorfiny w dużej dawce i ich zastosowanie jako środka przeciwbólowego PL2611445T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37999610P 2010-09-03 2010-09-03
EP11758027.4A EP2611445B1 (en) 2010-09-03 2011-09-02 High dose buprenorphine compositions and use as analgesic
PCT/US2011/050413 WO2012031252A1 (en) 2010-09-03 2011-09-02 High dose buprenorphine compositions and use as analgesic

Publications (1)

Publication Number Publication Date
PL2611445T3 true PL2611445T3 (pl) 2018-12-31

Family

ID=44653567

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11758027T PL2611445T3 (pl) 2010-09-03 2011-09-02 Kompozycje buprenorfiny w dużej dawce i ich zastosowanie jako środka przeciwbólowego

Country Status (11)

Country Link
US (1) US9168251B2 (pl)
EP (1) EP2611445B1 (pl)
JP (1) JP5938409B2 (pl)
AU (1) AU2011295694B2 (pl)
CA (1) CA2808237C (pl)
CY (1) CY1120920T1 (pl)
DK (1) DK2611445T3 (pl)
ES (1) ES2688577T3 (pl)
PL (1) PL2611445T3 (pl)
PT (1) PT2611445T (pl)
WO (1) WO2012031252A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2877155T (pt) 2012-07-26 2020-12-18 Camurus Ab Formulações de opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
ES2965836T3 (es) * 2018-01-22 2024-04-17 Foresee Pharmaceuticals Co Ltd Composición farmacéutica para administración de liberación mantenida de buprenorfina
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
JP3701693B2 (ja) * 1993-12-28 2005-10-05 日本製薬株式会社 鎮痛薬含有注射用徐放性脂肪乳剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO1999012606A1 (en) * 1997-09-08 1999-03-18 Becton Dickinson And Company Iontophoretic delivery of buprenorphine
GB0201367D0 (en) * 2002-01-22 2002-03-13 Ml Lab Plc Composition
CA2529983C (en) * 2003-07-25 2010-07-20 Euro-Celtique S.A. Preoperative treatment of post operative pain
BRPI0618891A2 (pt) * 2005-11-21 2011-09-13 Schering-Plough Ltd. composições farmacêuticas
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
CN102143736A (zh) * 2008-07-17 2011-08-03 梅里亚有限公司 增强聚原酸酯和它们的制剂的稳定性的方法

Also Published As

Publication number Publication date
EP2611445B1 (en) 2018-08-15
JP5938409B2 (ja) 2016-06-22
US9168251B2 (en) 2015-10-27
AU2011295694B2 (en) 2015-02-05
ES2688577T3 (es) 2018-11-05
US20140329843A1 (en) 2014-11-06
AU2011295694A1 (en) 2013-03-14
DK2611445T3 (en) 2018-10-22
CA2808237C (en) 2019-08-06
CA2808237A1 (en) 2012-03-08
PT2611445T (pt) 2018-10-24
WO2012031252A1 (en) 2012-03-08
JP2013536872A (ja) 2013-09-26
CY1120920T1 (el) 2019-12-11
EP2611445A1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2646468A4 (en) ANTI-NGF COMPOSITIONS AND THEIR USE
ZA201209156B (en) Therapeutic oral composition
ZA201209259B (en) Uses and compositions
PH12013500698A1 (en) Hair-mending compositions and associated methods
SI2579875T1 (sl) Sestavki obsegajoči buprenorfin
IL222576A0 (en) Fexofenadine-based composition and preparation process therefor
AP3441A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
EP2685993A4 (en) PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF
PL2521445T3 (pl) Preparat i jego zastosowanie
EP2601269A4 (en) ANTI-ABSORPTION COMPOSITIONS AND METHOD FOR THEIR USE
ZA201302012B (en) Low dose pharmaceutical composition
GB201018650D0 (en) Methods and compositions
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
EP2544542A4 (en) PAIN COMPOUNDS, COMPOSITIONS AND THEIR USE
PT2611445T (pt) Composições de buprenorfina de dose elevada e utilização como analgésico
IL221501A (en) Medicinal product containing miramistine
GB201005826D0 (en) New compositions and their use
GB201003741D0 (en) Methods and therapeutic compositions
IL220796A0 (en) Compositions and methods for treating gliblastoma gbm
AU2010901846A0 (en) Therapeutic methods and compositions
GB201018651D0 (en) Methods and compositions